Zimmer Biomet Holdings (ZBH) Tops Q2 EPS by 3c

Zimmer Biomet Holdings (NYSE: ZBH) reported Q2 EPS of $1.90, $0.03 better than the analyst estimate of $1.87. Revenue for the quarter came in at $2.03 billion versus the consensus estimate of $1.98 billion.

"Our performance in the second quarter improved meaningfully from the first quarter 2021 across all regions and product categories as recovery from the global pandemic continued to take hold. While we anticipate some ongoing COVID-19 pressure, we expect continued improvement in procedure volume recovery through the second half of 2021," said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. "Against this backdrop, Zimmer Biomet has continued to execute, investing in our business, expanding our portfolio and developing and launching innovative products designed to improve mobility and health. This execution enables ZB to build and deliver value for our customers and shareholders and to move our mission forward for the patients we ultimately serve."

GUIDANCE:

Zimmer Biomet Holdings sees FY2021 EPS of $7.65-$7.95, versus prior guidance of $7.60-$8.00 and the consensus of $7.86.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• Adidas (ADDYY) gains after outlook boost
• Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
• UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up